The plant, dubbed Modulus, represents an investment of approximately $600 million and is set to be fully operational by mid-2026.
The facility is designed to produce up to four vaccines or biopharmaceuticals simultaneously and can be reconfigured within days, compared to the months or years typically required for traditional plants.
The expansion supports Singapore’s efforts to strengthen its vaccine manufacturing capacity.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.